ArticleJAMA dermatology2017

JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.

Maulik Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.